Taste and smell disturbances in patients with gastrointestinal stromal tumors using tyrosine-kinase inhibitors.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON21230

Enrollment

Registered

2019-06-25

Start date

2019-07-15

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastro-intestinal stromal tumors

Interventions

Patients will be interviewed by phone about taste alterations. Information about the background of the patients, including gender, age and type and treatment of the GIST, will be collected from the pa

Eligibility

Inclusion criteria

Inclusion criteria: - Pathologically confirmed diagnosis of a GIST - Currently treated with imatinib, sunitinib or regorafenib - Able to understand spoken and written Dutch - Ability to comprehend and complete questionnaire by phone - > 18 years

Exclusion criteria

Exclusion criteria: - No oral food intake - Coexisting-morbidities affecting taste or smell function - Uncertainty about the willingness or ability of the patient to comply with the protocol requirements

Design outcomes

Primary

Measure	Time frame
What is the prevalence of taste and smell disturbances in GIST patients using TKIs?	—

Secondary

Measure	Time frame
What is the type of taste and smell disturbances in GIST patients using TKIs? What is the association between taste and smell disturbances and impact on daily life and QoL? What are the differences between imatinib, sunitinib and regorafenib in taste and smell disturbances? What is the association between taste and smell disturbances and the duration of the TKI use?	—

Contacts

Public ContactJacco de Haan

University Medical Center Groningen

j.j.de.haan@umcg.nl050-361281

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)